727 related articles for article (PubMed ID: 17253916)
1. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
2. [Tegaserod in treatment of women with irritable bowel syndrome].
Munck LK; Ainsworth MA
Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome.
Baker DE
Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185
[TBL] [Abstract][Full Text] [Related]
4. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
5. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
[TBL] [Abstract][Full Text] [Related]
6. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger C
Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
[TBL] [Abstract][Full Text] [Related]
7. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
8. Review article: the safety profile of tegaserod.
Schoenfeld P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
[TBL] [Abstract][Full Text] [Related]
9. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
Bardhan KD; Forbes A; Marsden CL; Mason T; Short G
Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702
[TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
11. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
Layer P; Keller J; Mueller-Lissner S; Rüegg P; Loeffler H
Digestion; 2005; 71(4):238-44. PubMed ID: 16024929
[TBL] [Abstract][Full Text] [Related]
12. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC; Barghout V; McBurney CR; Niecko TE
Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
[TBL] [Abstract][Full Text] [Related]
13. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
Khoshoo V; Armstead C; Landry L
Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297
[TBL] [Abstract][Full Text] [Related]
14. Drug therapy options for patients with irritable bowel syndrome.
Talley NJ
Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
[TBL] [Abstract][Full Text] [Related]
16. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
Tegaserod Clinical Research Group
Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
[TBL] [Abstract][Full Text] [Related]
18. Tegaserod treatment for IBS: a model of indirect costs.
Smith DG; Barghout V; Kahler KH
Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
[TBL] [Abstract][Full Text] [Related]
19. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.
Al-Judaibi B; Chande N; Gregor J
Can J Clin Pharmacol; 2010; 17(1):e194-200. PubMed ID: 20410554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
